Sanofi received FDA approval for a new manufacturing line to expand production of Beyfortus, a preventive therapy for respiratory syncytial virus in infants.
Beyfortus is the first long-acting monoclonal antibody approved by the FDA to prevent RSV-related lower respiratory tract disease in newborns and infants as well as children up to 24 months old, according to a Sept. 16 news release from the drug manufacturer.
Sanofi has started shipping doses to private healthcare providers and the CDC's Vaccines for Children program, the release said.